drugset / Trial / NCT00928421

An Open-label, Single-dose Pilot Study to Evaluate Varisolve® (Polidocanol Endovenous Microfoam (PEM)) 0.125% [0.2%] for Varicose Veins

NCT00928421

Phase 2 Completed 16 enrolled Boston Scientific Corporation
NaSingle-groupOpen-labelTreatment

Summary

To determine the effect and safety of Varisolve® 0.125% \[0.2%\]

Timeline

Start
2009-06
Primary completion
2009-12
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Polidocanol Other / unclassified 0.125 % Intravenous

Indications